Stock Market News for May 29, 2026
314 news published.
Biotech and Big Pharma Headlines
Bristol Myers Squibb (BMY) said its CELMoD mezigdomide cut risk of progression or death by more than 50% versus standard of care in relapsed/refractory multiple myeloma — a result likely to reshape treatment sequencing and expectations for BMY's oncology franchise.
Johnson & Johnson (JNJ) added to its lung‑cancer momentum: new data show RYBREVANT® (amivantamab‑vmjw) plus LAZCLUZE® (lazertinib) delivers prolonged benefit as a first‑line option for atypical EGFR‑mutated non‑small cell lung cancer. Investors will watch how this expands JNJ's targeted‑therapy TAM and competitive dynamics with other EGFR regimens.
Johnson & Johnson (JNJ) also released new TECVAYLI® (teclistamab‑cqyv) data showing superior progression‑free and overall survival as early as first relapse in multiple myeloma, strengthening the drug's long‑term revenue potential.
Pfizer (PFE) reported a seven‑year LORBRENA CROWN analysis showing the longest progression‑free survival to date in advanced non‑small cell lung cancer, reinforcing durable value for targeted therapies.
AbbVie (ABBV) received European Commission authorization to expand the label for VENCLYXTO® (venetoclax) to include additional combinations in previously untreated CLL — a regulatory win widening AbbVie's hematology market.
MannKind (MNKD) won FDA approval for Afrezza as the first and only inhaled mealtime insulin approved for children aged 6 and older, expanding the addressable population if uptake and payor coverage follow.
Clinical Data and Diagnostics
Tempus (TEM) notched two material updates: the company received FDA approval for its tumor‑only xT CDx, and announced initial multimodal foundation model results for oncology insight generation — combining diagnostic clearance with AI outputs that could scale reimbursable services.
Oculis (OCS) reported topline DIAMOND Phase 3 results for OCS‑01 in diabetic macular edema. Positive, practice‑moving readouts in DME can open a commercial ophthalmology pathway and influence partnership or licensing discussions.
Veracyte (VCYT) said the OPTIMA trial shows Prosigna identifies high‑risk breast cancer patients who can safely avoid chemotherapy — a potential practice‑changing result that could lift diagnostic volumes and shift treatment economics for early‑stage breast cancer.
Corcept (CORT) presented ASCO 2026 data showing Lifyorli™ overall‑survival benefits across subgroups in platinum‑resistant ovarian cancer, including recent taxane‑exposed patients. Survival signals in resistant populations can materially affect late‑stage valuation and partnering leverage.
Moleculin (MBRX) presented ASCO data showing no detectable cardiotoxicity with annamycin despite high exposure — a safety profile that may broaden dosing latitude and investigator interest.
Diagnostics and AI in Life Sciences
An analysis titled "The Next Great AI Revolution May Be Drug Delivery" highlights ML in formulation and targeting. Meanwhile, industry research such as ISG on AI collaboration suggests faster enterprise adoption that could lower R&D and commercialization friction.
AI and Enterprise Technology
OpenText (OTEX) joined the OECD Global Safe AI Reporting Framework, reducing regulatory execution risk and enhancing enterprise sales credibility.
Cognizant (CTSH) opened TriZetto Unify to AI agents to speed payer‑provider workflows, which can improve contract renewals and lower customer churn in healthcare IT.
Comcast (CMCSA)'s Xfinity was ranked #1 nationally by Opensignal for consistent quality and download speed — a retention and monetization lever for broadband.
Corporate Actions, M&A and Financing
CoStar Group (CSGP) moved closer to expanding residential intelligence after MidOcean agreed to sell Zonda to CoStar — a tuck‑in that broadens data in new‑home markets.
Scotiabank (BNS) agreed to acquire MapleMark Bank, sharpening access to specialty commercial banking flows.
Palomar Holdings (PLMR) completed a June 1 reinsurance placement that strengthens capital and supports risk‑adjusted growth.
CBL Properties (CBL) announced a $71.9 million non‑recourse loan secured by Hamilton Place in Chattanooga — a capital move to shore up liquidity for a regional mall owner navigating retail headwinds.
QXO (QXO) launched cash tender offers and consent solicitations tied to TopBuild Corp.'s 2032 and 2034 notes, a financing and restructuring action that could reshape debt metrics for the borrower and affect creditor recoveries.
Olaplex (OLPX) filed a notice of settlement of shareholder derivative actions, resolving litigation risk that can clear a path for corporate governance normalization and budget predictability.
Cuprina Holdings (CUPR) completed a reverse stock split and requested a Nasdaq Hearings Panel hearing to maintain listing — an event that directly affects liquidity and investor access.
Market Alerts & Unusual Activity
Genius Group (GNS) issued a response to unusual market activity, flagging trading spikes that can presage volatility or regulatory review.
Sinovac (SVA) received a Nasdaq notice for a late 2025 annual report, a compliance flag that investors should monitor for potential delisting risk or remediation timelines.
Fathom Holdings (FTHM) also received a Nasdaq notification over a late 10‑Q filing, another governance item that can influence short‑term liquidity and investor confidence.
Technology, Mobility and Defense Tech
ChargePoint (CHPT) partnered with Powers Parts to simplify fast charging for transit operators, advancing electrification in public fleets and recurring revenue potential.
Ondas (ONDS) secured over $30 million in new orders in May, bringing Q2 orders above $110 million across defense and autonomous platforms — a meaningful backlog signal.
DarkIris (DKI) launched an AIGC video platform integrating ByteDance’s Seedance 2.0, reflecting rising commercialization of generative video tools among enterprise AI vendors.
Energy, Utilities, Maritime and Infrastructure
Kennametal (KMT) announced measures to strengthen its balance sheet and enhance liquidity, reducing refinancing risk.
Duke Energy (DUK) said Duke Energy Florida will implement a third rate reduction to lower residential bills by about 25% in 2026, a material change for regulated earnings mix.
Nordic American Tankers Ltd (NAT) updated stakeholders on the situation in the Middle East and disclosed an insider purchase, offering operational context and a management confidence signal amid geopolitical risk.
Integra Resources (ITRG) announced the publication of a federal Notice of Intent for the Delamar project, a permitting milestone that de‑risks timing ahead of financing decisions.
Nexa (NEXA) provided an update on its Cajamarquilla operation, with production and operational notes investors watch for commodity exposure and project cadence.
Dynagas LNG Partners LP (DLNG) reported Q1 results, updating on cash flow and vessel utilization in a charter‑rate‑sensitive sector.
Consumer and Retail
Duluth Trading Co. (DLTH) expanded its online and in‑store "Garden Shop" with protective apparel and durable gear, a seasonal merchandising push aimed at repeat engagement.
Lanvin (LANV) named Barbara Werschine as CEO, a leadership change that could affect brand strategy and wholesale partnerships.
Health Systems, Payers and Policy
UnitedHealthcare (UNH) said it will remove nearly two‑thirds of prior authorization requirements for pediatric care, a policy change that could lower provider administrative burden and affect utilization trends.
Labcorp (LH) is backing a multi‑institution trial to expand genetic testing in colorectal cancer, an initiative that could lift diagnostics volumes if successful.
Selected Smaller‑Cap and Strategic Updates
Forum (FRMM) received initiation of analyst coverage with a $10.00 price target from Sidoti, a visibility boost for micro‑cap investors.
Avidbank (AVBH) continues strategic growth initiatives and expanded its team, signaling local commercial banking organic growth.
Steakholder Foods (STKH) announced a $1.1 million warrant exercise, a small cap cash infusion.
Crescent Biopharma (CBIO) disclosed inducement awards, routine hiring incentives for biotech startups.
Removed or Downgraded Items
Routine filings, minor conference notices and low‑impact operational press releases have been condensed or dropped to keep the focus on regulatory approvals, material clinical readouts, sizable order wins, and strategic financing or M&A moves that drive stock and sector outlooks.
Stay ahead of the market with our list of today's most important stock news and financial updates. Whether you're a day trader, long-term investor, or market enthusiast, our news feed covers everything you need to know about publicly traded companies.
Our news feed is designed for investors who want to stay informed about the latest developments affecting their portfolio or watchlist. Whether you're researching potential investments, monitoring your current holdings, or simply staying up-to-date with market trends, our stock news page provides the information you need to make informed decisions.
What You'll Find on This Page:
- Breaking financial news and market-moving headlines
- FDA approvals and clinical trial results for biotech and pharma stocks
- Stock offerings, dividends, and other corporate actions
- Mergers, acquisitions, and strategic partnerships
- Business news affecting company performance and stock prices
- Easy-to-use tags for quick news categorization
- Stock tickers for instant company identification
- AI sentiment analysis to gauge market reaction
- Estimated impact scores to assess potential stock movement